Biotechnology

MetaVia

MetaVia released FY2026 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.79 (forecast USD -0.755)

MetaVia released FY2025 Annual Earnings on March 26 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -7.3499 (forecast USD -8.8866)

MetaVia released FY2025 Q4 earnings on March 26 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.8503 (forecast USD -1.82)

MetaVia released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.54 (forecast USD -2.75)

MetaVia released FY2025 9 Months Earnings on November 6, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.7613

MetaVia Announces Positive Phase 1 Trial Results for Obesity Drug DA-1726

MetaVia Inc. to Present Progress of Drug DA-1726

MetaVia released FY2025 Semi-Annual earnings on August 7 (EST), actual revenue USD 0, actual EPS USD -6.5933

MetaVia released FY2025 Q2 earnings on August 7 (EST), actual revenue USD 0, actual EPS USD -0.2613 (forecast EPS USD -0.2233)

MetaVia Launches DA-1726 Drug Study

MetaVia and SyntekaBio Collaborate to Explore DA-1241 Indications

MetaVia Begins Phase 1 Trial for DA-1726

Metavia Inc. elects directors and approves private placement

MetaVia Announces Clinical Pre-trial Data for MASH Drug Combination Therapy

MetaVia CEO Participates in Life Science Virtual Investor Forum

MetaVia DA-1241 to be presented at ADA Scientific Sessions

MetaVia Presents Innovative Cardiometabolic Therapy Presentation

East Asia ST Ltd Acquires Common Stock of MetaVia Inc.

Maxim Group Maintains MetaVia Buy Rating

MetaVia released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -3.96 (forecast USD -6.71)

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

OceanPal

TLSA

MTVA

LABU

Healthcare stocks rose on Tuesday, with the NYSE Healthcare Index up 1.1% and the State Street Healthcare Select Sector SPDR ETF gaining 1.2%. Nourish raised $100 million in Series C funding. Boston Scientific shares increased 1.4% after positive trial results, while Relay Therapeutics saw a 5.2% rise following promising drug data. Tiziana Life Sciences' shares rose 3.7% based on favorable clinical data. MetaVia's shares surged 58% after three abstracts were accepted for presentation at the American Diabetes Association's 2026 Scientific Sessions.

Fidelity

Tiziana Life Sciences

Boston Scientific

Direxion S&P Biotech Bull 3X

VG Health

Health Care Select Sector SPDR

iShares Biotechnology ETF

JPMorgan Chase

Relay Therapeutics

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Sector Update: Healthcare Stocks Rise Tuesday Afternoon

AMIX

IBBQ

On Tuesday, Med Pharmaceuticals (NASDAQ:INM) saw a 127% increase to $1.54, while MetaVia (NASDAQ:MTVA) rose 58.54% to $1.76. Other gainers included Co-Diagnostics (NASDAQ:CODX) up 41.6% and Edesa Biotech (NASDAQ:EDSA) up 32.11%. Conversely, WORK Medical Tech Gr (NASDAQ:WOK) dropped 39% to $0.23, and Autonomix Medical (NASDAQ:AMIX) fell 25.43%. AIM ImmunoTech (AMEX:AIM) declined 18.02% to $0.33.

benzinga_article

Autonomix Medical

WORK Medical Tech

Edesa Biotech

Co-Diagnostics

AIM ImmunoTech

iShares US Medical Devices

VanEck Biotech ETF

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Adial Pharmaceuticals

Virax Biolabs

Akanda

Psyence Biomedical

Quantum Cyber NV

AIM IMMUNOTECH INC

AIM ImmunoTech Inc.

PSYENCE BIOMEDICAL LTD C/WTS 25/01/2029(TO PUR COM)

Mainz Biomed NV

12 Health Care Stocks Moving In Tuesday's Intraday Session

VRAX

ARKG

SBIO

In Tuesday's pre-market session, MetaVia (MTVA) shares surged 50.5% to $1.67, while Virax Biolabs (VRAX) rose 38.68% to $0.33. Karyopharm Therapeutics (KPTI) increased by 21.98% to $8.71. Conversely, WORK Medical Tech (WOK) fell 38.1% to $0.24, and Onconetix (ONCO) decreased by 24.77% to $0.23. Several companies reported Q1 earnings recently, impacting stock movements.

Onconetix

Karyopharm Therap

Ark Genomic Revolution ETF

SPDR S&P Health Equip

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

iShares US Pharma

Jasper Therapeutics

Hyperliquid Strategies

Purple Biotech

Sunshine Biopharma

Wellgistics Health

Picard Medical

GeoVax Labs

SUNSHINE BIOPHARMA INC C/WTS (TO PUR COM)

GEOVAX LABS INC C/WTS 29/09/2025(TO PUR COM)

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Earnings Watch

MetaVia | 8-K: FY2026 Q1 Revenue: USD 0

MetaVia Inc. (Nasdaq: MTVA) announced that a late-breaking abstract on DA-1726, a GLP-1/glucagon dual agonist for obesity treatment, has been accepted for a poster presentation at the EASL Congress 2026 in Barcelona. The presentation will highlight DA-1726's potential as a best-in-class treatment, currently evaluated in a Phase 1 study. The company aims to optimize dosing and tolerability, with results expected in Q4 2023. DA-1726 has shown promising pre-clinical results, outperforming leading GLP-1 receptor agonists in weight loss and metabolic benefits.

StockTitan

MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026 | MTVA Stock News

MetaVia Inc. has announced the dosing of the first patient in Part 3 of its Phase 1 clinical trial for DA-1726, a dual oxyntomodulin analog aimed at treating obesity. The trial will involve 40 participants and assess safety, tolerability, and metabolic measures over 16 weeks. Previous data indicated a 9% weight loss at 48 mg with favorable tolerability. Despite positive updates, analysts rate MTVA stock as Neutral due to weak financial performance and ongoing losses, with a price target of $8.00.

Tip Ranks

MetaVia Advances DA-1726 Obesity Trial With First Patient